Literature DB >> 18628457

Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591.

Sridhar Vempati1, Carola Reindl, Ulla Wolf, Ruth Kern, Konstantin Petropoulos, Vegi M Naidu, Christian Buske, Wolfgang Hiddemann, Tobias M Kohl, Karsten Spiekermann.   

Abstract

PURPOSE: Mutations in the receptor tyrosine kinase FLT3 are found in up to 30% of acute myelogenous leukemia patients and are associated with an inferior prognosis. In this study, we characterized critical tyrosine residues responsible for the transforming potential of active FLT3-receptor mutants and ligand-dependent activation of FLT3-WT. EXPERIMENTAL
DESIGN: We performed a detailed structure-function analysis of putative autophosphorylation tyrosine residues in the FLT3-D835Y tyrosine kinase domain (TKD) mutant. All tyrosine residues in the juxtamembrane domain (Y566, Y572, Y589, Y591, Y597, and Y599), interkinase domain (Y726 and Y768), and COOH-terminal domain (Y955 and Y969) of the FLT3-D835Y construct were successively mutated to phenylalanine and the transforming activity of these mutants was analyzed in interleukin-3-dependent Ba/F3 cells. Tyrosine residues critical for the transforming potential of FLT3-D835Y were also analyzed in FLT3 internal tandem duplication mutants (FLT3-ITD)and the FLT3 wild-type (FLT3-WT) receptor. RESULT: The substitution of the tyrosine residues by phenylalanine in the juxtamembrane, interkinase, and COOH-terminal domains resulted in a complete loss of the transforming potential of FLT3-D835Y-expressing cells which can be attributed to a significant reduction of signal tranducer and activator of transcription 5 (STAT5) phosphorylation at the molecular level. Reintroduction of single tyrosine residues revealed the critical role of Y589 and Y591 in reconstituting interleukin-3-independent growth of FLT3-TKD-expressing cells. Combined mutation of Y589 and Y591 to phenylalanine also abrogated ligand-dependent proliferation of FLT3-WT and the transforming potential of FLT3-ITD-with a subsequent abrogation of STAT5 phosphorylation.
CONCLUSION: We identified two tyrosine residues, Y589 and Y591, in the juxtamembrane domain that are critical for the ligand-dependent activation of FLT3-WT and the transforming potential of oncogenic FLT3 mutants.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18628457     DOI: 10.1158/1078-0432.CCR-07-1873

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  7 in total

Review 1.  Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases.

Authors:  Kenneth Verstraete; Savvas N Savvides
Journal:  Nat Rev Cancer       Date:  2012-10-18       Impact factor: 60.716

2.  c-Cbl and Cbl-b ligases mediate 17-allylaminodemethoxygeldanamycin-induced degradation of autophosphorylated Flt3 kinase with internal tandem duplication through the ubiquitin proteasome pathway.

Authors:  Gaku Oshikawa; Toshikage Nagao; Nan Wu; Tetsuya Kurosu; Osamu Miura
Journal:  J Biol Chem       Date:  2011-07-18       Impact factor: 5.157

Review 3.  Differential signaling of Flt3 activating mutations in acute myeloid leukemia: a working model.

Authors:  Perry M Chan
Journal:  Protein Cell       Date:  2011-02-25       Impact factor: 14.870

4.  Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling.

Authors:  Deepika Arora; Sabine Stopp; Sylvia-Annette Böhmer; Julia Schons; Rinesh Godfrey; Kristina Masson; Elena Razumovskaya; Lars Rönnstrand; Simone Tänzer; Reinhard Bauer; Frank-D Böhmer; Jörg P Müller
Journal:  J Biol Chem       Date:  2011-01-24       Impact factor: 5.157

Review 5.  Platelet-derived growth factors and their receptors: structural and functional perspectives.

Authors:  Po-Han Chen; Xiaoyan Chen; Xiaolin He
Journal:  Biochim Biophys Acta       Date:  2012-11-05

6.  Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.

Authors:  Hanna Janke; Friederike Pastore; Daniela Schumacher; Tobias Herold; Karl-Peter Hopfner; Stephanie Schneider; Wolfgang E Berdel; Thomas Büchner; Bernhard J Woermann; Marion Subklewe; Stefan K Bohlander; Wolfgang Hiddemann; Karsten Spiekermann; Harald Polzer
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

7.  OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia.

Authors:  Houda Alachkar; Wendy Stock; Bartholomew J Eisfelder; Caner Saygin; Joseph Wynne; Margaret W Colton; Mariafausta Fischietti; Elspeth M Beauchamp; Jason X Cheng; Olatoyosi Odenike; Gail Roboz
Journal:  Blood Cancer J       Date:  2021-03-03       Impact factor: 11.037

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.